Bone Metastases

  • Marko Popovic
  • Michael Poon
  • Erin Wong
  • Danielle Rodin
  • Kenneth Li
  • Florence Mok
  • Edward Chow
Part of the Medical Radiology book series (MEDRAD)


Bone is one of the most common sites of metastasis. This chapter addresses three notable issues for bone metastases patients receiving radiotherapy: prognosis, complications affecting this patient population and predictive factors for various toxicities. Overall survival estimates for bone metastases patients have improved considerably over the past 50 years and vary with respect to primary tumour location. Numerous general and tumour-specific predictors influence survival in this patient population; when combined, these covariates have been used to develop relevant predictive models for survival. Toxicities in bone metastases patients are generally mild, and risk is determined by radiation site and dose. One noteworthy toxicity that has garnered significant research in recent years is radiotherapy-induced nausea and vomiting, for which risk factors include the anatomic site being irradiated, a greater radiotherapy field size, a female gender and anxiety. Complications that may affect bone metastases patients are spinal cord compression, impending or pathologic fractures, neuropathic pain and recurrence of bone metastasis. In closing, this chapter contains essential information that should be considered in the delivery of treatment; ultimately, however, treatment choice should be tailored to the individual patient and should be based on a variety of clinical and sociodemographic factors.


Bone Metastasis Neuropathic Pain Pathologic Fracture Spinal Cord Compression Edmonton Symptom Assessment System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abrahm JL, Banffy MB, Harris MB (2008) Spinal cord compression in patients with advanced metastatic cancer. J Am Med Assoc 299(8):937–946CrossRefGoogle Scholar
  2. Akimoto S et al (1999) Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade. Prostate 38:28–34PubMedCrossRefGoogle Scholar
  3. Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N et al (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15(3):455–459PubMedCrossRefGoogle Scholar
  4. Altundag MB, Ucer AR, Calikoglu T, Guran Z (2002) Single (500 cGy, 800 cGy) and multifraction (300 X 10 cGy) radiotherapy schedules in the treatment of painful bone metastases. Turk J Hematol Oncol 12:16–21Google Scholar
  5. Amouzegar-Hashemi F, Behrouzi H, Kazemian A et al (2008) Single versus multiple fractions of palliative radiotherapy for bone metastases: a randomized clinical trial in Iranian patients. Curr Oncol 15:151PubMedCentralPubMedGoogle Scholar
  6. Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, Kim YW, Heo DS (2012) Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 77(3):572–577PubMedCrossRefGoogle Scholar
  7. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198PubMedCrossRefGoogle Scholar
  8. Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M et al (2012) Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist 17(5):645–652PubMedCentralPubMedCrossRefGoogle Scholar
  9. Bone Pain Trial Working Party (1999) 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with multi-fraction schedule over 12 months of patient follow-up. Radiother Oncol 52(2):111–121CrossRefGoogle Scholar
  10. Brasso K, Christensen IJ, Johansen JS, Teisner B, Garnero P, Price PA et al (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66(5):503–513PubMedCrossRefGoogle Scholar
  11. Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69PubMedCrossRefGoogle Scholar
  12. Brown JE, Cook RJ, Lipton A, Coleman RE (2012) Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients. Clin Cancer Res 18(22):6348–6355PubMedCrossRefGoogle Scholar
  13. Chow E, Fung KW, Panzarella T, Bezjak A, Danjoux C, Tannock I (2002) A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 53(5):1291–1302PubMedCrossRefGoogle Scholar
  14. Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25(11):1423–1436PubMedCrossRefGoogle Scholar
  15. Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, Tannock I (2008) Predictive model for survival in patients with advanced cancer. J Clin Oncol 26(36):5863–5869PubMedCrossRefGoogle Scholar
  16. Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P, Tannock I (2009) Validation of a predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 73(1):280–287PubMedCrossRefGoogle Scholar
  17. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S (2012) Update on the systemic review of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 24(2):112–124CrossRefGoogle Scholar
  18. Coates A, Abraham SK, Kaye SB (1983) On the receiving end: patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203PubMedCrossRefGoogle Scholar
  19. Cole D (1989) A randomized trial of a single treatment versus conventional fractionation in the palliative radiotherapy of painful bone metastases. Clin Oncol 1:59–62CrossRefGoogle Scholar
  20. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588–1594PubMedCrossRefGoogle Scholar
  21. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRefGoogle Scholar
  22. Coleman R, Rubens R (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 77:336–340CrossRefGoogle Scholar
  23. Coleman RE, Smith P, Rubens RD (1998) Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 77(2):336–340PubMedCentralPubMedCrossRefGoogle Scholar
  24. Crawford E, Eisenberger M, McLeod K (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424PubMedCrossRefGoogle Scholar
  25. Danjoux CE, Rider WD, Fitzpatrick PJ (1979) The acute radiation syndrome. A memorial to William Michael Court–Brown. Clin Radiol 30:581–584PubMedCrossRefGoogle Scholar
  26. Dennis K, Maranzano E, De Angelis C et al (2011a) Radiotherapy-induced nausea and vomiting. Exp Rev Pharmacoecon Outcomes Res 11:685–692CrossRefGoogle Scholar
  27. Dennis K, Chow E, Roos D, DeAngelis C, Hartsell W, van der Linden Y, Hoskin P (2011b) Should bone metastases causing neuropathic pain be treated with single-dose radiotherapy? Clin Oncol 23(7):482–484CrossRefGoogle Scholar
  28. Eisenberger M, Crawford E, Wolf M (1994) Prognostic factors in stage D2 prostate cancer: important implications for future trials. Semin Oncol 21:613–619PubMedGoogle Scholar
  29. El-Shenshawy H, Kandeel A, El-Essawy S (2006) The effect of a single fraction compared to multiple fractions radiotherapy on painful bone metastases with evaluation of computed tomography bone density in osteolytic bone metastases. Bull Alex Fac Med 42:439Google Scholar
  30. Enblom A, Bergius AB, Steineck G, Hammar M, Borjeson S (2009) One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 17(1):23–32PubMedCrossRefGoogle Scholar
  31. Feyer PC, Stewart AL, Titlbach OJ (1998) Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer 6(3):253–260PubMedCrossRefGoogle Scholar
  32. Feyer PC, Maranzano E, Molassiotis A, Roila F, Clark-Snow RA, Jordan K (2011) Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 19(Suppl. 1):S5–S14PubMedCrossRefGoogle Scholar
  33. Foro P, Algara M, Reig A et al (1998) Randomized prospective trial comparing three schedules of palliative radiotherapy. Preliminary results. Oncologia 21:55–60Google Scholar
  34. Foro P, Fontanals AV, Galceran JC et al (2008) Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol 89:150–155CrossRefGoogle Scholar
  35. Galasko CSB (1986) Skeletal metastases. Butterworths, LondonGoogle Scholar
  36. Gaze MN, Kelly CG, Kerr GR et al (1997) Pain relief and quality of life following radiotherapy for bone metastases: a randomized trial of two fractionation schedules. Radiother Oncol 45:109–116PubMedCrossRefGoogle Scholar
  37. Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA (1999) Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 79(1):15–20PubMedCrossRefGoogle Scholar
  38. Hamouda WE, Roshdy W, Teema M (2007) Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases. Gulf J Oncol 1:35–41Google Scholar
  39. Harada H, Katagiri H, Kamata M, Yoshioka Y, Asakura H, Hashimoto T, Furutani K, Takahashi M, Sakahara H, Nishimura T (2010) Radiological response and clinical outcome in patients with femoral bone metastases after radiotherapy. J Radiat Res 51(2):131–136PubMedCrossRefGoogle Scholar
  40. Harrington KD (1988) Prophylactic management of impending fractures. In: Harrington KD (ed) Orthopaedic management of metastatic bone disease. CV Mosby, St. LouisGoogle Scholar
  41. Hartsell W et al (2005) Randomized trial of short versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97:798–804PubMedCrossRefGoogle Scholar
  42. Hatse S, Lambrechts D, Verstuyf A, Smeets A, Brouwers B, Vandorpe T et al (2012) Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 33(7):1319–1326PubMedCrossRefGoogle Scholar
  43. Holt T, Hoskin P, Maranzano E, Sahgal A, Schild SE, Ryu S, Loblaw A (2012) Malignant epidural spinal cord compression: the role of external beam radiotherapy. Curr Opin Support Palliat Care 6(1):103–108PubMedCrossRefGoogle Scholar
  44. Iordanidou L, Trivizaki E, Saranti S et al (2006) Is there a role of whole body bone scan in early stages of non small cell lung cancer patients. J Buon 11:491–497PubMedGoogle Scholar
  45. Izumi K, Mizokami A, Itai S, Shima T, Shigehara K, Miwa S et al (2012) Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis. BJU Int 109(3):394–400PubMedCrossRefGoogle Scholar
  46. Jarvis GK, Northcott HC (1987) Religion and differences in morbidity and mortality. Soc Sci Med 25:813–824PubMedCrossRefGoogle Scholar
  47. Jawad MU, Scully SP (2010) In brief: classifications in brief: Mirels’ classification: metastatic disease in long bones and impending pathologic fracture. Clin Orthop Relat Res 468(10):2825–2827PubMedCentralPubMedCrossRefGoogle Scholar
  48. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P et al (2004) Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 111(5):783–791PubMedCrossRefGoogle Scholar
  49. Kaasa S, Brenne E, Lund J et al (2006) Prospective randomized multicentre trial on single fraction radiotherapy (8 Gy X 1) versus multiple fractions (3 Gy X 10) in the treatment of painful bone metastases: Phase III randomized trial. Radiother Oncol 79:278–284PubMedCrossRefGoogle Scholar
  50. Kagei K, Suzuki K, Shirato H et al (1990) A randomized trial of single and multifraction radiation therapy for bone metastasis: a preliminary report. Gan No Rinsho 36:2553–2558PubMedGoogle Scholar
  51. Kerba M, Wu JS, Duan Q, Hagen NA, Bennett MI (2010) Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy. J Clin Oncol 28(33):4892–4897PubMedCrossRefGoogle Scholar
  52. Komatsu T, Kunieda E, Oizumi Y, Tamai Y, Akiba T (2012) An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy? Neoplasma 59(6):650–657PubMedCrossRefGoogle Scholar
  53. Kwok Y, Regine WF, Patchell RA (2005) Radiation therapy alone for spinal cord compression: time to improve upon a relatively ineffective status quo. J Clin Oncol 23(15):3308–3310PubMedCrossRefGoogle Scholar
  54. Landis S et al (1999) Cancer statistics. CA Cancer J Clin 49:8–29PubMedCrossRefGoogle Scholar
  55. Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF et al (2011) Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA. 14. J Clin Oncol 29(27):3605–3610PubMedCrossRefGoogle Scholar
  56. Llobera J, Esteva M, Rifa J et al (2000) Terminal cancer: duration and prediction of survival time. Eur J Cancer 36:2036–2043PubMedCrossRefGoogle Scholar
  57. Lo SS, Holden L, Lutz ST, Liu RK, Chow E (2010) Should all patients with uncomplicated bone metastases be treated with a single 8-gy fraction? Exp Rev Pharmacoecon Outcomes Res 10(2):95–98CrossRefGoogle Scholar
  58. Loblaw DA, Perry J, Chambers A, Laperriere NJ (2005) Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the cancer care Ontario practice guidelines initiative’s neuro-oncology disease site group. J Clin Oncol 23(9):2028–2037PubMedCrossRefGoogle Scholar
  59. Maltoni M, Caraceni A, Brunelli C et al (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the steering committee of the European Association for Palliative Care. J Clin Oncol 23:6340–6348CrossRefGoogle Scholar
  60. Maranzano E, Bellavita R, Rossi R, DeAngelis V, Frattegiani A, Bagnoli R et al (2005) Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 23(15):3358–3365PubMedCrossRefGoogle Scholar
  61. Maranzano E, De Angelis V, Pergolizzi S et al (2010) A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94(1):36–41PubMedCrossRefGoogle Scholar
  62. Matzkin H, Perito P, Soloway M (1993) Prognostic factors in metastatic prostate cancer. Cancer 72(suppl 12):3788–3792PubMedCrossRefGoogle Scholar
  63. Morris PG, Ulaner GA, Eaton A et al (2012) Standardized uptake value by position emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer 118(22):5454–5462PubMedCrossRefGoogle Scholar
  64. Nielson O et al (1998) Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 47:233–240CrossRefGoogle Scholar
  65. Ozsaran Z, Yalman D, Anacek Y et al (2001) Palliative radiotherapy in bone metastases: results of a randomized trial comparing three fractionation schedules. J Buon 6:43–48Google Scholar
  66. Perez JE, Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Rodriguez R, Cuevas MA, Alvarez LA (1990) Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. Am J Clin Oncol 13:294–298PubMedCrossRefGoogle Scholar
  67. Phillips DP, Smith DG (1990) Postponement of death until symbolically meaningful occasions. J Am Med Assoc 263:1947–1951CrossRefGoogle Scholar
  68. Plunkett TA, Rubens RD (2005) Clinical features and prognosis of bone metastases. In: Jasmin C, Coleman RE, Coia LR, Capanna R, Saillant G (eds) Textbook of bone metastases. Wiley, ChichesterGoogle Scholar
  69. Popovic M et al (2012) Comparing prognostic factors in patients with spinal metastases: a literature review. Exp Rev Pharmacoecon Outcomes Res 12(3):345–356CrossRefGoogle Scholar
  70. Price P, Hoskin PJ, Easton D et al (1986) Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 6:247–255PubMedCrossRefGoogle Scholar
  71. Priestman TJ, Priestman SG (1984) An initial evaluation of Nabilone in the control of radiotherapy-induced nausea and vomiting. Clin Radiol 35(4):265–266PubMedCrossRefGoogle Scholar
  72. Priestman TJ, Roberts JT, Lucraft H et al (1990) Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol 2(2):71–75CrossRefGoogle Scholar
  73. Rades D, Abrahm JL (2010) The role of radiotherapy for metastatic epidural spinal cord compression. Nat Rev Clin Oncol 7(10):590–598PubMedCrossRefGoogle Scholar
  74. Rades D, Fehlauer F, Schulte R, Veninga T, Stalpers LJ, Basic H et al (2006) Prognostic factors for local control and survival after radiotherapy of metastatic spinal cord compression. J Clin Oncol 24(21):3388–3393PubMedCrossRefGoogle Scholar
  75. Rades D, Rudat V, Veninga T, Stalpers LJ, Basic H, Karstens JH et al (2008) A score predicting post treatment ambulatory status in patients irradiated for metastatic spinal cord compression. Int J Radiat Oncol Biol Phys 72(3):905–908PubMedCrossRefGoogle Scholar
  76. Reuben DB, Mor V, Hiris J (1988) Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 148:1586–1591PubMedCrossRefGoogle Scholar
  77. Robson M, Dawson N (1996) How is androgen-dependent metastatic prostate cancer best treated? Hemat Oncol Clin North Am 10:727–747CrossRefGoogle Scholar
  78. Roos D et al (2005) Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). Radiother Oncol 75:54–63PubMedCrossRefGoogle Scholar
  79. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150–3157PubMedCrossRefGoogle Scholar
  80. Ruggieri P, Mavrogenis AF, Casadei R, Errani C, Angelini A, Calabro T (2010) Protocol of surgical treatment of long bone pathologic fractures. Injury 41(11):1161–1167PubMedCrossRefGoogle Scholar
  81. Sabbatini P et al (1999) Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 17:948–957PubMedGoogle Scholar
  82. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  83. Sarkar SK, Sarkar S, Pahari B et al (2002) Multiple and single fraction palliative radiotherapy in bone secondaries: a prospective study. Ind J Radiol Imag 12:281–284Google Scholar
  84. Schoenbach VJ, Kaplan BH, Fredman L et al (1986) Social ties and mortality in Evans County, Georgia. Am J Epidemiol 123:577–591PubMedGoogle Scholar
  85. Sejpal SV, Bhate A, Small W (2007) Palliative radiation therapy in the management of brain metastases, spinal cord compression, and bone metastases. Semin Intervent Radiol 24(4):363–374PubMedCentralPubMedCrossRefGoogle Scholar
  86. Shaham D, Breuer R, Copel L et al (2006) Computed tomography screening for lung cancer: applicability of an international protocol in a single-institution environment. Clin Lung Cancer 7:262–267PubMedCrossRefGoogle Scholar
  87. Shiue K, Sahgal A, Chow E, Lutz ST, Chang EL, Mayr NA et al (2010) Management of metastatic spinal cord compression. Expert Rev Anticancer Ther 10(5):697–708PubMedCrossRefGoogle Scholar
  88. Solomayer EF, Diel IJ, Meyberg GC, Gollan Ch, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastases. Breast Cancer Res Treat 59:271–278PubMedCrossRefGoogle Scholar
  89. Soloway M, Hardeman S, Hickey D (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61:195–202PubMedCrossRefGoogle Scholar
  90. Steenland E et al (1999) The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 52:101–109PubMedCrossRefGoogle Scholar
  91. The Italian Group for Antiemetic Research in Radiotherapy (1999) Radiation-induced emesis: a prospective observational multicenter Italian trial. Int J Radiat Oncol Biol Phys 44(3):619–625CrossRefGoogle Scholar
  92. Toscani F, Brunelli C (2005) Predicting survival in terminal cancer patients: clinical observation or quality-of-life evaluation? Palliat Med 19:220–227PubMedCrossRefGoogle Scholar
  93. Urch CE, Dickenson AH (2008) Neuropathic pain in cancer. Eur J Cancer 44(8):1091–1096PubMedCrossRefGoogle Scholar
  94. Wedin R (2001) Surgical treatment for pathologic fractures. Acta Orthop Scand 72(Suppl 302):1–29CrossRefGoogle Scholar
  95. Yamashita K, Ueda T, Komatsubara Y, Koyama H, Inaji H, Yonenobu K, Ono K (1991) Breast cancer with bone-only metastases: visceral metastases-free rate in relation to anatomic distribution of bone metastases. Cancer 68:634–637PubMedCrossRefGoogle Scholar
  96. Yamashita K, Ueda T, Komatsubara Y, Koyama H, Inaji H, Ono K, Yonenobu K (1992) A classification of bone metastases from breast cancer. In: Uchida A, Ono K (eds) Recent advances in musculoskeletal oncology. Springer, BerlinGoogle Scholar
  97. Zhang L, Teng Y, Zhang Y et al (2012) Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. J Clin Pathol 65:36–40PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Marko Popovic
    • 1
  • Michael Poon
    • 1
  • Erin Wong
    • 1
  • Danielle Rodin
    • 1
  • Kenneth Li
    • 2
  • Florence Mok
    • 3
  • Edward Chow
    • 1
  1. 1.Rapid Response Radiotherapy Program, Department of Radiation OncologyUniversity of Toronto, Odette Cancer Centre, Sunnybrook Health Sciences CentreTorontoCanada
  2. 2.Department of Clinical OncologyQueen Elizabeth HospitalHong Kong SARChina
  3. 3.Department of Clinical OncologyPrince of Wales HospitalHong Kong SARChina

Personalised recommendations